An artificial blood is basically a material used to fill and mimic some functions of real blood. It aims to give an alternative for red blood cell transfusions that is moving blood or plasma-based products from one human to another. But unlike it, a pure blood product is not manufactured artificially and there are no regulations in place with regards to its manufacture. This is the main reason why artificial blood has been seen as a possible risk on the part of patients who have undergone this procedure.
Scientists all over the world have been invited to attend a conference on stem cells, due to its great impact in the field of medicine and technology. At the same time, there is a great need for artificial blood, as more experts in different fields are coming up with new discoveries concerning its use in the field of medicine. It can be safely said that scientists in the United States are presently engaged in the process of learning how stem cells can be used to replace the defective or destroyed red blood cells. The key to this particular event is the advancement of medical science; more progress in this field means that we will find better treatments for diseases and illness in the future.
Artificial Blood Market Development
Continuous progress are being made in the global artificial blood market with respect to developing a suitable method to produce blood cells. Moreover, scientists have been trying to produce artificial blood from various molecules ranging from perfluorocarbons to hemoglobin. With the introduction of research in stem cells, scientist began to develop RBCs from stem cells of cord blood. For instance, the enrollment for the first clinical trials of stem-cell based red blood cells began in 2009. This study used stem cells from cord blood and adult bone marrow. The study was conducted at the Hematological Laboratory at the University of Paris VI.
A similar research conducted by scientists at the University of Bristol and the UK’s National Health Service (NHS) using stem cells from adult and umbilical cord blood has shown successful results from initial studies. The study is scheduled to enter clinical trials with 20 subjects in 2017. The focus of these trials is to offer special treatment for specific patient groups, rather than act as complete replacement for blood.
Artificial Blood Market Potential
According to the World Health Organization (WHO), there are around 50,000 stem cell transplantations performed annually worldwide, which include 2,000 cord blood hematopoietic stem cell transplants performed each year. Use of stem cells from cord blood is increasing, as it does not require perfect human leukocyte antigen (HLA) tissue matching, can be used allogenically, and has less incidence of graft v/s host disease. According to the New York Blood Center (NYBC), which is the largest cord blood bank globally in terms of units stored, over half of all stem cell transplants in children, in the U.S., use cord blood. A similar statistic has been noted among adults in Japan.
Post the trial in 2017, production is projected to commence in the following 8 to 10 years, thus prolonging the commercialization of product in the artificial blood market.
Artificial Blood Market Future Outlook
Cord blood stem cell transplantation has proved to be a successful therapy in treatment of around 70 diseases. Developing artificial blood can support the growing need to meet the demand-supply gap in blood transfusion, more so considering the fact that finding compatible donors for sickle cell anemia and thalassemia patients is a mammoth task. Production of artificial blood could be the most viable solution to address the unmet needs among these patients. Continued investment in research and development is crucial for ensuring the commercial application of this technology, a very critical factor to contribute towards development of artificial blood market. Being a critical therapy for a severe life condition, the artificial blood market is expected to get a product in a decade or so.
Key players in the artificial blood market are highly engaged in research and development activities to expand their product portfolio. For instance, in May 2019, Baxter International announced new research on 3-in-1 Oxiris filter Set for continuous renal replacement therapy (CRRT) and sepsis management. The filter removes cytokines and endotoxins from the blood.
Major Key players are also focused on conducting clinical trials to assess the efficacy of blood systems. For instance, in June 2018, Cerus Corporation presented its European Phase 3 study that evaluated the efficacy and safety of INTERCEPT-treated red blood cells (RBCs) in thalassemia major patients, at the 23rd Congress of European Hematology Association (EHA) in Stockholm, Sweden.
Additionally, in December 2018, Cerus Corporation announced the initiation and first patient enrollment in a Phase III study to evaluate the efficacy and safety of the INTERCEPT Blood System for red blood cells in patients undergoing complex cardiac surgery procedures.
Table of Content
Chapter 1 Industry Overview
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Global Artificial Blood Market Size Analysis from 2021 to 2027
11.6 COVID-19 Outbreak: Artificial Blood Industry Impact
Chapter 2 Global Artificial Blood Competition by Types, Applications, and Top Regions and Countries
2.1 Global Artificial Blood (Volume and Value) by Type
2.3 Global Artificial Blood (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global Artificial Blood Sales, Consumption, Export, Import by Regions (2016-2021)
Chapter 5 North America Artificial Blood Market Analysis
Chapter 6 East Asia Artificial Blood Market Analysis
Chapter 7 Europe Artificial Blood Market Analysis
Chapter 8 South Asia Artificial Blood Market Analysis
Chapter 9 Southeast Asia Artificial Blood Market Analysis
Chapter 10 Middle East Artificial Blood Market Analysis
Chapter 11 Africa Artificial Blood Market Analysis
Chapter 12 Oceania Artificial Blood Market Analysis
Chapter 13 South America Artificial Blood Market Analysis
Chapter 14 Company Profiles and Key Figures in Artificial Blood Business
Chapter 15 Global Artificial Blood Market Forecast (2021-2027)
Chapter 16 Conclusions
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027